Matthew Biegler
Stock Analyst at Oppenheimer
(3.18)
# 1,147
Out of 5,135 analysts
91
Total ratings
39.02%
Success rate
5.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Outperform | $36 → $50 | $29.42 | +69.98% | 7 | Feb 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $750 → $865 | $792.16 | +9.20% | 1 | Feb 2, 2026 | |
| RLAY Relay Therapeutics | Upgrades: Outperform | $14 | $9.10 | +53.85% | 7 | Jan 26, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $22.41 | +114.19% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $24.69 | +82.26% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $10.83 | +38.50% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $10.69 | +105.80% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $15.48 | +80.88% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.59 | +403.14% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $5.41 | +29.39% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.27 | +296.48% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $13.20 | +1,112.12% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $11.82 | +280.71% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $152.74 | -24.71% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $30.92 | +71.41% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.40 | +733.33% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $6.64 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $10.94 | +27.97% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.88 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.37 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $11.56 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.23 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.48 | - | 2 | Dec 22, 2022 |
Tyra Biosciences
Feb 3, 2026
Maintains: Outperform
Price Target: $36 → $50
Current: $29.42
Upside: +69.98%
Regeneron Pharmaceuticals
Feb 2, 2026
Reiterates: Outperform
Price Target: $750 → $865
Current: $792.16
Upside: +9.20%
Relay Therapeutics
Jan 26, 2026
Upgrades: Outperform
Price Target: $14
Current: $9.10
Upside: +53.85%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $22.41
Upside: +114.19%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $24.69
Upside: +82.26%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $10.83
Upside: +38.50%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $10.69
Upside: +105.80%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $15.48
Upside: +80.88%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.59
Upside: +403.14%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $5.41
Upside: +29.39%
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $2.27
Upside: +296.48%
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $13.20
Upside: +1,112.12%
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $11.82
Upside: +280.71%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $152.74
Upside: -24.71%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $30.92
Upside: +71.41%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.40
Upside: +733.33%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $6.64
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $10.94
Upside: +27.97%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.88
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.37
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $11.56
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.23
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.48
Upside: -